Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetShares Repurchased
Ratios

BridgeBio Pharma (BBIO) Leases (2020 - 2025)

BridgeBio Pharma's Leases history spans 6 years, with the latest figure at $8.1 million for Q4 2025.

  • For Q4 2025, Leases rose 41.3% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $8.1 million, up 41.3%, while the annual FY2025 figure was $8.1 million, 41.3% up from the prior year.
  • Leases for Q4 2025 was $8.1 million at BridgeBio Pharma, up from $6.6 million in the prior quarter.
  • Across five years, Leases topped out at $17.1 million in Q3 2021 and bottomed at $5.8 million in Q4 2024.
  • The 5-year median for Leases is $9.6 million (2023), against an average of $10.2 million.
  • The largest annual shift saw Leases surged 77.4% in 2021 before it crashed 32.87% in 2022.
  • A 5-year view of Leases shows it stood at $15.9 million in 2021, then plummeted by 32.87% to $10.7 million in 2022, then dropped by 24.83% to $8.0 million in 2023, then fell by 28.15% to $5.8 million in 2024, then skyrocketed by 41.3% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Leases are $8.1 million (Q4 2025), $6.6 million (Q3 2025), and $6.2 million (Q2 2025).